Pipeline

We are pursuing a broad and deep pipeline with the potential to address 80 percent of the world’s
cancers by incidence. Explore our oncology-focused pipeline, dedicated to addressing the most
pressing challenges in cancer care.

Pipeline

We are pursuing a broad and deep pipeline with the potential to address 80 percent of the world’s cancers by incidence. Explore our oncology-focused pipeline, dedicated to addressing the most pressing challenges in cancer care.

Download full pipeline
Area of interest
Solid Tumors
Hematologic Malignancies
Area of interest
Solid Tumors
Hematologic Malignancies
Planned
Ongoing
Completed

Filters

Filter
Development phase
Phase 1
Phase 2
Phase 3
Molecule
BGB-10188
BGB-16673
BGB-A333
BGB-DXP593
Ociperlimab
Pamiparib
Sonrotoclax
Tislelizumab
Zanubrutinib
Compound type
ADC
Bi/Tri-specific
Cytokine therapy
mAb
Protein degrader
Small molecule

1Amgen collaboration; BeiGene has China commercial rights. 2Ensem collaboration; BeiGene has global rights. 3DualityBio collaboration; BeiGene has global clinical, manufacturing, and commercialization rights. 4Leads Biolabs collaboration; BeiGene has global research, development, and manufacturing rights, and exclusive commercialization rights outside of China. 5Zymeworks/Jazz collaboration; BeiGene has exclusive development and commercialization rights in Asia (except Japan), Australia, and New Zealand. 6Amgen collaboration; BeiGene has development and commercialization rights in China. 7Amgen collaboration; BeiGene has development and commercialization rights in China. aIn combination with Zanubrutinib. bMay include: PD-1 mAb, LAG3 mAb, OX40 mAb, TIM3 mAb, HPK1 inhibitor. * Trial is listed on clinicaltrials.gov, but may not have subjects enrolled.